Bavarian Nordic (OTCMKTS:BVNRY) Shares Down 7.4% – Time to Sell?

Bavarian Nordic (OTCMKTS:BVNRY)’s stock price traded down 7.4% during trading on Wednesday . The company traded as low as $10.50 and last traded at $10.50. 1,212 shares traded hands during trading, a decline of 63% from the average daily volume of 3,289 shares. The stock had previously closed at $11.3440.

Bavarian Nordic Trading Down 3.2%

The company has a market cap of $2.49 billion, a price-to-earnings ratio of 10.57 and a beta of 1.20. The firm has a 50-day moving average price of $9.80 and a 200 day moving average price of $9.77.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings results on Friday, August 21st. The company reported $0.46 earnings per share (EPS) for the quarter. The business had revenue of $316.47 million for the quarter. Bavarian Nordic had a return on equity of 12.06% and a net margin of 24.36%.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.